Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19

NCT04732949 is registered in ClinicalTrials.gov with Synairgen Research Ltd. as lead sponsor.

NCT NCT04732949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04732949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19
Lead sponsor
Synairgen Research Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 12, 2021
Completion date
February 10, 2022
Enrollment
623 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, severe acute respiratory syndrome coronavirus 2